Our Upper GI Cancer Centre brings together specialists who work as one team to plan your care. Here is what that team offers:
Below, our oncologists answer the questions patients most often ask in the consultation room, organised by topic with the most important questions first.
Upper gastrointestinal (GI) cancer refers to cancers that start in the upper digestive tract: the esophagus, stomach, pancreas, liver, gallbladder, bile ducts and the first part of the small intestine (duodenum).
The main types of upper GI cancer are esophageal, stomach, pancreatic, liver, biliary tract (gallbladder and bile duct) and small bowel cancers, each with its own subtypes.
| Cancer Type | Organ Affected | Most Common Subtypes |
|---|---|---|
| Esophageal cancer | Food pipe (esophagus) | Squamous cell carcinoma; adenocarcinoma (often linked to Barrett’s esophagus) |
| Stomach (gastric) cancer | Stomach, including the gastroesophageal (GE) junction | Adenocarcinoma (intestinal and diffuse types); GIST; lymphoma; neuroendocrine tumors |
| Pancreatic cancer | Pancreas | Pancreatic ductal adenocarcinoma (PDAC); pancreatic neuroendocrine tumors (PNETs) |
| Liver cancer | Liver | Hepatocellular carcinoma (HCC); intrahepatic cholangiocarcinoma |
| Biliary tract cancer | Gallbladder and bile ducts | Gallbladder cancer; cholangiocarcinoma (perihilar/Klatskin, distal) |
| Small bowel cancer | Duodenum and small intestine | Duodenal/ampullary adenocarcinoma; neuroendocrine (carcinoid) tumors |
Many upper GI cancers can be cured when they are found early and can be completely removed, usually with surgery combined with chemotherapy or radiation.
Your chance of cure depends mainly on these factors:
How quickly upper GI cancer spreads differs between cancer types and between individual patients; pancreatic and diffuse-type stomach cancers tend to grow and spread more quickly than some other types.
The symptoms most often reported with stomach and esophageal cancer are difficulty swallowing, persistent indigestion or heartburn, feeling full quickly and unexplained weight loss. Many of these symptoms also have common, non-cancer causes.
Jaundice (yellowing of the skin and eyes), upper abdominal or back pain and unexplained weight loss are among the most common symptoms of pancreatic, liver and bile duct cancers.
| Symptom | Pancreatic Cancer | Liver Cancer | Bile Duct / Gallbladder Cancer |
|---|---|---|---|
| Jaundice | Common (head of pancreas) | Possible | Very common |
| Upper abdominal pain radiating to back | Common | Right-sided pain | Right-sided pain |
| Dark urine, pale stools, itching | Common | Possible | Very common |
| New-onset diabetes after age 50 | Possible warning sign | Uncommon | Uncommon |
| Abdominal swelling (ascites) | Advanced disease | Common | Advanced disease |
| Weight loss and fatigue | Very common | Common | Common |
Most acidity and indigestion is not caused by cancer. However, indigestion that lasts more than a few weeks, or occurs with warning signs, should be checked by a doctor, who may recommend an endoscopy.
See a doctor promptly if you notice any of these warning signs:
Upper GI cancer usually develops from a combination of genetic changes, long-term inflammation and environmental or lifestyle factors, and in most cases no single cause can be identified.
| Risk Factor | Cancers Most Linked |
|---|---|
| Tobacco (smoking and chewing) | Esophageal, stomach, pancreatic, liver |
| Alcohol | Esophageal (squamous), liver, pancreatic |
| Helicobacter pylori (H. pylori) infection | Stomach cancer, gastric lymphoma |
| Chronic acid reflux (GERD) and Barrett’s esophagus | Esophageal adenocarcinoma |
| Hepatitis B and C, fatty liver disease, cirrhosis | Liver cancer (HCC) |
| Gallstones, chronic gallbladder inflammation | Gallbladder cancer |
| Obesity and type 2 diabetes | Esophageal, pancreatic, liver |
| Chronic pancreatitis | Pancreatic cancer |
| Diets high in salt, smoked or preserved foods; low fruit and vegetable intake | Stomach and esophageal cancer |
| Very hot beverages | Esophageal squamous cell cancer |
An estimated 5–10% of upper GI cancers are linked to inherited gene changes, and genetic counseling is advised when there is a strong family history or a diagnosis at a young age.
H. pylori infection is the strongest known risk factor for stomach cancer and is classified as a Group 1 carcinogen by the International Agency for Research on Cancer (IARC), the World Health Organization’s cancer agency.
Upper GI cancer is confirmed with a biopsy, and imaging and blood tests are then used to find the exact type and stage and to plan the best treatment.
| Step | Test | Why It Is Done |
|---|---|---|
| 1 | Upper GI endoscopy (OGD) | Directly views the esophagus, stomach and duodenum and takes biopsies |
| 2 | Biopsy and histopathology | Confirms cancer and identifies the exact type and grade |
| 3 | CT scan (chest, abdomen, pelvis) | Shows tumor size, lymph nodes and spread to other organs |
| 4 | Endoscopic ultrasound (EUS) | Measures tumor depth and nearby nodes; guides pancreatic biopsy |
| 5 | PET-CT scan | Looks for hidden spread; used selectively |
| 6 | MRI / MRCP | Detailed imaging of the liver, pancreas and bile ducts |
| 7 | Tumor markers (CEA, CA 19-9, AFP) | Support diagnosis and help monitor treatment response |
| 8 | Staging laparoscopy | Checks for microscopic spread to the abdominal lining before major surgery |
| 9 | Biomarker and genetic testing | Identifies targets for immunotherapy and targeted therapy |
Most upper GI cancer tests take under an hour, need a few hours of fasting beforehand, and report results within a few days to two weeks.
| Test | Time Needed | Preparation | Typical Result Time |
|---|---|---|---|
| Upper GI endoscopy | 15–30 minutes (plus recovery from sedation) | Fast 6–8 hours; bring an escort | Visual findings same day |
| Biopsy report | Not applicable | Taken during endoscopy or EUS | 3–7 working days |
| CT scan | 15–30 minutes | Fast about 4 hours; kidney function test for contrast | 1–2 days |
| Endoscopic ultrasound (EUS) | 30–60 minutes | Fast 6–8 hours; review blood thinners | Findings same day; biopsy 3–7 days |
| PET-CT scan | 2–3 hours in total | Fast about 6 hours; avoid strenuous exercise; blood sugar check | 1–2 days |
| MRI / MRCP | 30–60 minutes | Fast 4–6 hours; declare any metal implants | 1–2 days |
| Biomarker / genetic testing | Not applicable | Uses existing biopsy tissue or a blood sample | 1–3 weeks |
Typical timeframes only. Your hospital will give you exact instructions; always follow the advice given for your appointment.
For most patients, treatment for upper GI cancer begins within about two to four weeks of diagnosis, once staging tests are complete and the tumor board has agreed a plan.
| Stage | What Happens | Typical Timeframe |
|---|---|---|
| First consultation | History, examination and review of existing reports | Week 1 |
| Diagnostic and staging tests | Endoscopy, biopsy, scans and blood tests | Weeks 1–2 |
| Tumor board review | Specialists agree on a personalized treatment plan | Weeks 2–3 |
| Treatment planning visit | Plan explained; consent; nutrition and fitness assessment | Weeks 2–3 |
| Treatment start | Surgery, chemotherapy or chemoradiation begins | Weeks 2–4 |
Timelines vary with test availability and your health.
Endoscopy and biopsy are usually done under sedation, and most patients feel little or no discomfort. The risk of a biopsy spreading cancer is considered very low, and the information it provides is essential for planning treatment.
Biomarkers are molecular features of your tumor that help predict which targeted therapy or immunotherapy is most likely to benefit you.
| Biomarker | Relevant Cancers | What It Can Mean for Treatment |
|---|---|---|
| HER2 | Stomach, GE junction, esophageal adenocarcinoma | Possible eligibility for trastuzumab-based targeted therapy |
| PD-L1 (CPS score) | Stomach, esophageal | Helps predict benefit from immunotherapy (nivolumab, pembrolizumab) |
| MSI-H / dMMR | All upper GI cancers | Often associated with strong responses to immunotherapy |
| Claudin 18.2 (CLDN18.2) | Stomach, GE junction | Possible eligibility for zolbetuximab |
| BRCA1/2, PALB2 | Pancreatic | May predict platinum chemotherapy sensitivity; PARP inhibitor (olaparib) maintenance |
| KRAS, NTRK, BRAF | Pancreatic, biliary | Guides targeted therapy and clinical trial options |
| FGFR2 fusions, IDH1 mutations | Cholangiocarcinoma | Possible eligibility for FGFR or IDH1 inhibitors |
Cancer stage describes how far the cancer has grown and spread, and it is one of the most important factors in choosing treatment and estimating outlook.
| Stage | General Meaning | Typical Treatment Goal |
|---|---|---|
| Stage 0 / I | Cancer limited to the inner layers of the organ | Cure; endoscopic resection or surgery |
| Stage II | Deeper growth or spread to a few nearby lymph nodes | Cure; surgery with chemotherapy and/or radiation |
| Stage III | Locally advanced; more lymph nodes or nearby tissues | Cure is possible for many patients with combined treatment |
| Stage IV | Spread to distant organs (liver, lungs, peritoneum) | Control cancer, extend life, relieve symptoms |
Survival rates for upper GI cancer vary widely by cancer type and stage, and they are generally much higher when cancer is found before it has spread.
| Cancer Type | Localized | Regional Spread | Distant Spread | All Stages |
|---|---|---|---|---|
| Stomach cancer | ~75% | ~35% | ~7% | ~36% |
| Esophageal cancer | ~49% | ~28% | ~6% | ~22% |
| Liver cancer | ~37% | ~13% | ~3% | ~22% |
| Pancreatic cancer | ~44% | ~16% | ~3% | ~13% |
Approximate 5-year relative survival from US SEER population data (diagnoses 2014–2020). These figures reflect patients treated in earlier years and cannot predict any individual’s outcome.
Stage 4 upper GI cancer is generally not curable, but it is treatable: chemotherapy, immunotherapy and targeted therapy can often shrink tumors, ease symptoms and extend life, and some patients achieve long-term control.
Upper GI cancer is treated with surgery, chemotherapy, radiation therapy, immunotherapy, targeted therapy and endoscopic or liver-directed procedures, usually in combination and tailored by a multidisciplinary team.
Surgery is recommended when the cancer is limited to one region and can be completely removed, and the type of operation depends on the organ involved.
| Surgery | Used For | What Is Removed |
|---|---|---|
| Esophagectomy (Ivor Lewis, McKeown) | Esophageal and GE junction cancer | Part or most of the esophagus; the stomach is shaped into a new food pipe |
| Subtotal (partial) gastrectomy | Lower stomach cancer | Lower part of the stomach with D2 lymph node dissection |
| Total gastrectomy | Upper or diffuse stomach cancer | Entire stomach; esophagus joined to the small intestine |
| Whipple procedure (pancreaticoduodenectomy) | Pancreatic head, ampullary, distal bile duct cancer | Head of pancreas, duodenum, gallbladder, part of bile duct |
| Distal pancreatectomy | Pancreatic body and tail cancer | Body/tail of pancreas, often with the spleen |
| Hepatectomy (liver resection) | Liver cancer, liver metastases | Part of the liver; the remaining liver regrows |
| Radical cholecystectomy | Gallbladder cancer | Gallbladder, part of the liver and lymph nodes |
| Liver transplant | Selected early liver cancer with cirrhosis | Entire diseased liver replaced |
Hospital stay after upper GI cancer surgery commonly ranges from one to fourteen days, depending on the operation, the surgical approach and how quickly you recover.
| Procedure | Typical Hospital Stay | Return to Light Activity | Typical Return to Desk Work |
|---|---|---|---|
| Endoscopic resection (EMR/ESD) | 1–3 days | Within 1 week | 1–2 weeks |
| Esophagectomy | 7–14 days | 4–6 weeks | 2–3 months |
| Subtotal or total gastrectomy | 5–10 days | 3–4 weeks | 6–10 weeks |
| Whipple procedure | 7–14 days | 4–6 weeks | 2–3 months |
| Distal pancreatectomy | 5–7 days | 3–4 weeks | 6–8 weeks |
| Liver resection (hepatectomy) | 5–7 days | 3–4 weeks | 6–8 weeks |
| Radical cholecystectomy | 4–7 days | 2–4 weeks | 4–8 weeks |
Minimally invasive approaches may shorten these times; complications may lengthen them.
Many upper GI cancer operations can be performed with laparoscopic (keyhole) or robotic techniques in suitable patients, and studies suggest cancer outcomes comparable to open surgery when performed by experienced teams.
For many locally advanced upper GI cancers, chemotherapy (sometimes with radiation) given before surgery can shrink the tumor, treat microscopic spread early and improve the chance of cure.
Chemotherapy for upper GI cancer is given in cycles, most commonly every two or three weeks, and a curative course typically lasts about three to six months.
| Regimen | Used For | How Often | Typical Course Length |
|---|---|---|---|
| FLOT | Stomach / GE junction (perioperative) | Every 2 weeks | 4 cycles before and 4 after surgery |
| CROSS (carboplatin + paclitaxel + radiation) | Esophageal (before surgery) | Chemotherapy weekly; radiation 5 days a week | 5 weeks |
| Modified FOLFIRINOX (adjuvant) | Pancreatic (after surgery) | Every 2 weeks | About 6 months (12 cycles) |
| Gemcitabine + nab-paclitaxel | Pancreatic (advanced) | Days 1, 8 and 15 of each 28-day cycle | Continued while effective and tolerated |
| Gemcitabine + cisplatin + durvalumab | Biliary tract (advanced) | Days 1 and 8 of each 21-day cycle | Up to 8 cycles, then durvalumab alone every 4 weeks |
| Atezolizumab + bevacizumab | Liver cancer (advanced HCC) | Every 3 weeks | Continued while effective and tolerated |
Examples only. Your regimen, doses and number of cycles are individualised by your oncologist.
Immunotherapy and targeted therapy are precision treatments matched to your tumor’s biomarkers, and they are part of standard care for many advanced upper GI cancers.
| Cancer | Immunotherapy / Targeted Options (examples) |
|---|---|
| Stomach & GE junction | Nivolumab or pembrolizumab with chemotherapy; trastuzumab (HER2+); zolbetuximab (CLDN18.2+) |
| Esophageal | Nivolumab or pembrolizumab with chemotherapy; adjuvant nivolumab after surgery |
| Liver (HCC) | Atezolizumab + bevacizumab; durvalumab + tremelimumab; lenvatinib; sorafenib |
| Biliary tract | Durvalumab or pembrolizumab with gemcitabine-cisplatin; FGFR2 and IDH1 inhibitors |
| Pancreatic | Olaparib maintenance (germline BRCA); immunotherapy for MSI-H tumors |
Drug approvals and availability vary by country. Your oncologist will advise which options apply to you.
Liver-directed therapies deliver treatment directly to the tumor while sparing healthy liver, and they are used when surgery is not suitable or as a bridge to transplant.
Curative treatment for upper GI cancer commonly takes about four to eight months from diagnosis to completion, although timelines vary from person to person.
Chemotherapy side effects are common, but most are temporary, and supportive medicines can prevent or reduce many of them.
| Side Effect | How It Is Managed |
|---|---|
| Nausea and vomiting | Preventive anti-nausea medicines before each cycle |
| Fatigue | Gentle activity, rest and treatment of anemia |
| Low blood counts / infection risk | Regular blood tests; growth factor injections when needed |
| Tingling or numbness (neuropathy) | Dose adjustment; avoiding cold drinks and cold exposure with oxaliplatin |
| Diarrhea or mouth sores | Medicines, hydration and a mouth care routine |
| Hair thinning or loss | Depends on the regimen; hair usually regrows after treatment ends |
| Immune-related effects (immunotherapy) | Early reporting; steroids or other medicines when needed |
Contact your care team immediately, or go to the nearest emergency department, if you develop a fever of 38°C (100.4°F) or higher, breathing difficulty, bleeding or symptoms that are rapidly getting worse during treatment.
| Symptom | What to Do | Urgency |
|---|---|---|
| Fever of 38°C (100.4°F) or higher, or chills | Call the 24-hour oncology helpline or go to the emergency department | Immediately |
| Breathlessness or chest pain | Call emergency services | Immediately |
| Vomiting blood or black, tarry stools | Go to the emergency department | Immediately |
| Unable to keep fluids down for 24 hours | Call the oncology helpline | Same day |
| More than 4–6 episodes of diarrhea a day | Call the oncology helpline | Same day |
| New yellowing of skin or eyes | Call your oncology team | Within 24 hours |
| Mild nausea, tiredness or mouth soreness | Follow your home-care advice; mention at your next visit | Routine |
Contact your care team urgently for these symptoms. In a life-threatening emergency, call your local emergency number.
Many patients can continue light work and everyday activities during chemotherapy, with adjustments around treatment days, while major surgery usually requires a longer break.
After upper GI surgery, dietitians commonly recommend small, frequent, protein-rich meals, about six to eight times a day, to maintain weight and reduce the risk of dumping syndrome.
Weight loss is common in upper GI cancer because of swallowing difficulty, poor digestion and the effects of the cancer itself, and early nutrition support can help you tolerate treatment better.
Current evidence does not show that sugar in a normal diet directly makes cancer grow faster, and highly restrictive “cancer diets” can lead to harmful weight and muscle loss.
Follow-up after upper GI cancer treatment is most frequent in the first two years, when the risk of the cancer returning is highest.
| Time After Treatment | Visit Frequency | Typical Tests |
|---|---|---|
| Years 1–2 | Every 3–6 months | Clinical review, blood tests, tumor markers; CT scan as indicated |
| Years 3–5 | Every 6–12 months | Clinical review, blood tests; imaging as indicated |
| After 5 years | Yearly | Nutrition review, vitamin levels, symptom check |
The risk of upper GI cancer coming back depends on the original stage, lymph node involvement and response to treatment, and when it does return, it most often does so within the first two to three years.
Many patients regain most of their energy within two to three months of major upper GI surgery, although full recovery can take longer.
Palliative care does not mean giving up; it is specialist medical care that controls symptoms and improves quality of life at any stage of cancer, and it can be given alongside active treatment.
Swallowing difficulty and jaundice can often be relieved with minimally invasive stents, radiation or bypass procedures.
| Problem | Treatment Options |
|---|---|
| Difficulty swallowing | Esophageal stent, radiation therapy, feeding tube |
| Stomach outlet blockage | Duodenal stent, EUS-guided gastrojejunostomy, surgical bypass |
| Jaundice from bile duct blockage | ERCP biliary stent, P drainage |
| Fluid in the abdomen (ascites) | Drainage (paracentesis), indwelling catheter |
| Bleeding from the tumor | Endoscopic therapy, radiation, embolization |
A second opinion is a common and accepted part of cancer care, and it can be especially valuable for complex upper GI cancers that may need major surgery.
Bring every report, scan and biopsy sample related to your diagnosis, because these allow the specialist to confirm your diagnosis and stage without repeating tests unnecessarily.
| Item | Why It Is Needed | Format |
|---|---|---|
| Biopsy report and slides/blocks | Allows our pathologists to confirm the diagnosis and test biomarkers | Original report; slides and blocks from the lab |
| Endoscopy / EUS reports | Shows tumor location and extent | Printed report, with photos if available |
| CT, MRI or PET-CT scans | Allows our radiologists to review staging | Images on CD/DVD or online link, plus reports |
| Blood test results | Checks organ function and tumor markers | Most recent printed or digital reports |
| Medication list | Identifies drug interactions and blood thinners | Names, doses and timing |
| Previous treatment summaries | Shows what has already been done | Discharge and treatment summaries |
| ID and insurance documents | Needed for registration and approvals | Government ID; insurance card or policy |
Clinical trials give eligible patients access to promising new cancer treatments under close monitoring, and eligibility depends on your cancer type, stage, biomarkers and overall health.
The most useful questions to ask your oncologist cover your exact diagnosis, stage, treatment goal, options, side effects and timeline.
Feeling shock, fear, anger or sadness after a cancer diagnosis is normal, and professional emotional support is an important part of cancer care.
Not every upper GI cancer can be prevented, but the risk of many can be lowered by addressing modifiable risk factors and screening people at higher risk.
Screening or surveillance is generally recommended for people at higher risk, including those with cirrhosis, chronic hepatitis B, Barrett’s esophagus or inherited cancer syndromes.
| High-Risk Group | Recommended Surveillance | Typical Interval |
|---|---|---|
| Cirrhosis or chronic hepatitis B | Liver ultrasound, with or without AFP blood test | Every 6 months |
| Barrett’s esophagus | Endoscopy with biopsies | Every 3–5 years without dysplasia; shorter with dysplasia |
| CDH1 gene carriers | Specialist counseling; preventive gastrectomy or intensive endoscopic surveillance | Individualised |
| BRCA2, PALB2, Lynch or strong family history of pancreatic cancer | Pancreatic MRI and/or EUS in expert centres | Usually yearly |
| Persistent reflux with warning signs | Upper GI endoscopy | As advised by your doctor |
Medical disclaimer: This information is for general education and does not replace personalised medical advice. Please consult a qualified oncologist about your specific diagnosis and treatment.
Medically reviewed by Dr Ashwin K.R. · Last reviewed: 10 October 2026
Medical disclaimer: This information is for general education and does not replace personalised medical advice. Please consult a qualified doctor about your specific diagnosis and treatment.